Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Cactus Jack who wrote (182232)	7/22/2002 11:41:00 PM
From: sammaster	Read Replies (1) \| Respond to of 436258

pfizer reps are really playing up the cardiac risk of vioxx... now with its purchase of pharmacia it will get bextra/celebrex and no longer have to pay royalties... im sure they will jettison the non-core assets of pharmacia like it did with WL and do stock buyback/reduce debt... pfizer marketing force can greatly increase sales of any product which is why it gets good comarketing deals like it did with celebrex and gets higher margin business by not having to invest so much in product development..this justifies the higher price/sales ratio